Navigation Links
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
Date:10/2/2008

PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

This compound originates from the work of Pharmaleads' chief scientists, Professors Bernard P. Roques and Marie-Claude Fournie-Zaluski, and is a dual inhibitor of both enzymes responsible for the rapid degradation of enkephalins, the endogenous opiates. It therefore elicits an analgesic effect wherever enkephalins are produced as a response to a painful stimulus, and maintains a high level of these natural analgesic substances by preventing their rapid degradation.

According to Thierry Bourbie, Chairman and CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the first representative of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug development company. Neuropathic pain remains poorly treated and there is an urgent need to develop and bring to patients and doctors a specific oral treatment that would be really active and well tolerated. This looks very promising."

Bernard P. Roques, Vice-President and CSO of Pharmaleads explains: "The inhibition of both enzymes, responsible for the inactivation, in the body, of naturally present opiates, enhances their analgesic properties. PL37 physiological action in all areas where pain is present leads to very promising properties in peripheral neuropathic disorders."

Michel Wurm, M.D., Director of Corporate Development at Pharmaleads stated: "Pre-clinical studies have demonstrated the safety and efficacy of PL37 across all known models for neuropathic pain. The bioavailability of this oral compound is remarkable, as is its safety margin. We hope to complete Phase I in less than a year, including early pharmacodynamic testing in healthy volunteers."

The pre-clinical program was financed with the support of OSEO, the French Public Research Financing Institution.

About Pharmaleads:

Pharmaleads is a pharmaceutical company focusing on research and early development of small molecules. Headquartered in Paris, France, Pharmaleads was founded in 2001 by Professors Bernard P. Roques, pharmacist and PhD in chemistry, Member of the French Academy of Sciences, and Marie-Claude Fournie-Zaluski, PhD in chemistry, both of them inventors of drugs (2 on the market). They were joined in 2004 by Thierry Bourbie, alumnus from Polytechnique and Mines, PhD from Stanford, (former Deputy General Manager, Suez Group) and Jean-Pierre Rogala, PhD from Agro, MBA from MIT (IBM, Suez Group). They were able to bring in their first rank international business expertise to fully unleash the world-class capabilities of the company in pharmacology and medicinal chemistry. In 2006, Michel Wurm, M.D. joined and added his extensive experience in drug and business development.

For further information, please contact:

PHARMALEADS YUCATAN

Michel Wurm, MD, Annie-Florence Loyer

Director, Corporate Development +33-1-53-63-27-29

+33-1-440-670-04 afloyer@yucatan.tm.fr

michel.wurm@pharmaleads.com

http://www.pharmaleads.com


'/>"/>
SOURCE Pharmaleads
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
4. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
9. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):